Molecular and structural consequences of early renal allograft injury

被引:113
作者
Baboolal, K
Jones, GA
Janezic, A
Griffiths, DR
Jurewicz, WA
机构
[1] Univ Wales Hosp, Welsh Transplant Res Grp, Cardiff CF14 4XW, S Glam, Wales
[2] Univ Wales Hosp, Dept Pathol, Cardiff CF14 4XW, S Glam, Wales
关键词
TGF-beta; interstitial fibrosis; chronic allograft nephropathy; fibrosis; kidney injury; cyclosporine;
D O I
10.1046/j.1523-1755.2002.00149.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Chronic allograft nephropathy is an important cause of graft failure. Many donor and recipient factors contribute to its development. Prospective analysis of these factors has been hindered by the lack of sensitive and specific indicators of renal injury. As a consequence protocol biopsies have been increasingly used in the assessment of renal allograft injury. We performed protocol renal allograft biopsies to prospectively examine the role of important determinants and mediators of chronic allograft nephropathy. Methods. A total of 51 consecutive cadaveric renal transplant recipients entered a randomized prospective study of tacrolimus (Tac) versus cyclosporine (CsA) microemulsion based immunosuppression. Study patients underwent protocol renal allograft biopsies at the time of engraftment and at 3, 6 and 12 months post-transplantation. Biopsies were analyzed by quantitative polymerase chain reaction (PCR) for mRNA for transforming growth factor-beta (TGF-beta), thrombospondin, and fibronectin. Measurements of renal structural injury were estimated by quantitative assessment of interstitial fibrosis and glomerulosclerosis. Changes in profibrotic growth factors and renal structural injury were related to donor and recipient determinants by stepwise regression analysis. Results. Longitudinal assessment of renal injury demonstrated an early and progressive increase in mRNA for TGF-beta, thrombospondin (TSP) and fibronectin (FBN): TGF-beta baseline, 1.9 +/- 0.2 log copies; TGF-beta 6 months, 2.5 +/- 0.2 log copies, P < 0.05 6 months vs. baseline; TSP baseline, 1.9 +/- 0.2 log copies; TSP 6 months, 2.4 +/- 0.2 log copies, P < 0.05 6 months vs. baseline; FBN baseline, 2.0 +/- 0.2 log copies; FBN 12 months, 2.3 +/- 0.2 log copies, P < 0.05 12 months vs. baseline. This increase in profibrotic growth factors within the allograft was associated with a significant increase in interstitial fibrosis (Vvi) on renal biopsies: Vvi baseline, 13 +/- 1%; Vvi 3 months, 18 +/- 1%; Vvi 6 months, 28 +/- 2%; Vvi 12 months, 34 +/- 2%; P < 0.05 3, 6, and 12 months vs. baseline. Histological analysis demonstrated chronic allograft nephropathy in 4% biopsies at 3 months, 12% at 6 months and in 49% at 12 months. These changes in renal structure were not associated with any change in creatinine clearance (C-Cr): C-Cr 3 months, 56 +/- 2 mL/min, Cc, 24 months, 56 2 mL/min; P = NS. Stepwise regression analysis of key donor and recipient determinants of chronic renal injury identified calcineurin inhibitors and acute rejection episodes as important factors involved in the development of chronic renal injury. In particular, the use of cyclosporine compared to tacrolimus was associated with a tenfold increase in TGF-beta mRNA (TGF-beta mRNA at 6 months, CsA vs. Tac, 3 +/- 0.3 vs. 2 +/- 0.3 log copies, P < 0.05), interstitial fibrosis (Vvi at 6 months, CsA vs. Tac, 33 +/- 4% vs. 24 +/- 2%, P < 0.05). Changes in growth factors and renal structure predicted impaired renal function (Cc, at 12 months, CsA vs. Tac, 53 +/- 4 mL/min vs. 62 2 mL/min, P < 0.05). Similarly, acute rejection episodes were associated with an accelerated development of interstitial fibrosis (Vvi at 6 months, acute rejection vs. no rejection, 34 +/- 3% vs. 25 +/- 2%; P < 0.05), but not with changes in TGF-beta, thrombospondin or fibronectin expression. Conclusion. Our results suggest that structural injury develops early in the natural history of the renal allograft and is mediated, in part, by the early up-regulation of profibrotic growth factors. We have determined that calcineurin inhibitors, in particular cyclosporine, and acute rejection episodes are key factors in the development of renal structural injury.
引用
收藏
页码:686 / 696
页数:11
相关论文
共 52 条
[1]   RISK-FACTORS FOR CHRONIC REJECTION IN RENAL-ALLOGRAFT RECIPIENTS [J].
ALMOND, PS ;
MATAS, A ;
GILLINGHAM, K ;
DUNN, DL ;
PAYNE, WD ;
GORES, P ;
GRUESSNER, R ;
NAJARIAN, JS ;
FERGUSON ;
PAUL ;
SCHAFFER .
TRANSPLANTATION, 1993, 55 (04) :752-757
[2]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[3]   CHARACTERISTICS OF EARLY ROUTINE RENAL-ALLOGRAFT BIOPSIES [J].
BURDICK, JF ;
BESCHORNER, WE ;
SMITH, WJ ;
MCGRAW, D ;
BENDER, WL ;
WILLIAMS, GM ;
SOLEZ, K .
TRANSPLANTATION, 1984, 38 (06) :679-684
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]  
CORAZZA GR, 1982, GASTROENTEROLOGY, V83, P1217
[6]   Impact of acute rejection and early allograft function on renal allograft survival [J].
Cosio, FG ;
Pelletier, RP ;
Falkenhain, ME ;
Henry, ML ;
Elkhammas, EA ;
Davies, EA ;
Bumgardner, GL ;
Ferguson, RM .
TRANSPLANTATION, 1997, 63 (11) :1611-1615
[7]   Thrombospondin-1 is a major activator of TGF-β1 in vivo [J].
Crawford, SE ;
Stellmach, V ;
Murphy-Ullrich, JE ;
Ribeiro, SMF ;
Lawler, J ;
Hynes, RO ;
Boivin, GP ;
Bouck, N .
CELL, 1998, 93 (07) :1159-1170
[8]  
DIMENY E, 1995, CLIN TRANSPLANT, V9, P79
[9]   Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Eckert, C ;
Landt, O ;
Taube, T ;
Seeger, K ;
Beyermann, B ;
Proba, J ;
Henze, G .
LEUKEMIA, 2000, 14 (02) :316-323
[10]   Increased expression of transforming growth factor-β1 and thrombospondin-1 in congenital hepatic fibrosis:: Possible role of the hepatic stellate cell [J].
El-Youssef, M ;
Mu, Y ;
Huang, LJ ;
Stellmach, V ;
Crawford, SE .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1999, 28 (04) :386-392